GEOFFREY XIAO: Open Payments
NPI 1790132017 · TIGARD, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$798 in 44 payments from 19 companies in 2025. Trend: 2023 $0 · 2024 $291 · 2025 $798
Food & beverage: $798
| Company | Payments | Amount |
|---|---|---|
| Calliditas Therapeutics US Inc. | 12 | $141 |
| AstraZeneca Pharmaceuticals LP | 5 | $93 |
| Mallinckrodt Hospital Products Inc. | 4 | $79 |
| Novartis Pharmaceuticals Corporation | 3 | $54 |
| SCPHARMACEUTICALS INC. | 2 | $50 |
| Amgen Inc. | 2 | $46 |
| Vifor Pharma, Inc. | 2 | $46 |
| Travere Therapeutics, Inc. | 2 | $42 |
| Medtronic, Inc. | 1 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
Products named: TARPEYO, ACTHAR, FARXIGA, FUROSCIX, Veltassa, Fabhalta, SYMPLICITY G3, JYNARQUE.
Industry payments across OR — which companies pay providers there.
